Advertisement

Quality of Life Issues in Patients Undergoing Cytoreductive Surgery and HIPEC

  • Julianna P. Englisch
  • Andreas Brandl
  • Ute Goerling
  • Beate Rau
Chapter

Abstract

Achieving or maintaining the quality of life of patients is an important goal especially if they are confronted with an end-stage oncologic disease. Peritoneal surface malignancy (PSM) as primary disease or secondary as peritoneal metastasis from different tumor origins is related to a bad prognosis. These patients suffer from ascites, fatigue, ileus, and cachexia, and in most of these patients, only palliative treatment is available. Extensive surgery combined with localized hyperthermic intraperitoneal chemotherapy (HIPEC) may lead to longer survival in selected patients. However, cytoreductive surgery (CRS) and HIPEC can be associated with severe complications and influences quality of life dramatically. In this chapter, we want to point out the quality of life issues in patients undergoing CRS and HIPEC.

Keywords

Cytoreductive surgery Hyperthermic intraperitoneal chemotherapy Quality of life 

References

  1. 1.
    Simkens GA, van Oudheusden TR, Luyer MD, Nienhuijs SW, Nieuwenhuijzen GA, Rutten HJ, de Hingh IH. Serious postoperative complications affect early recurrence after cytoreductive surgery and HIPEC for colorectal peritoneal carcinomatosis. Ann Surg Oncol. 2015;22(8):2656–62.CrossRefPubMedGoogle Scholar
  2. 2.
    Tsilimparis N, Bockelmann C, Raue W, Menenakos C, Perez S, Rau B, Hartmann J. Quality of life in patients after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: is it worth the risk? Ann Surg Oncol. 2013;20(1):226–32.CrossRefPubMedGoogle Scholar
  3. 3.
    Glehen O, Gilly FN, Boutitie F, Bereder JM, Quenet F, Sideris L, Mansvelt B, Lorimier G, Msika S, Elias D. Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1290 patients. Cancer. 2010;116(24):5608–18.CrossRefPubMedGoogle Scholar
  4. 4.
    Esquivel J, Lowy AM, Markman M, Chua T, Pelz J, Baratti D, Baumgartner JM, Berri R, Bretcha-Boix P, Deraco M, Flores-Ayala G, Glehen O, Gomez-Portilla A, Gonzalez-Moreno S, Goodman M, Halkia E, Kusamura S, Moller M, Passot G, Pocard M, Salti G, Sardi A, Senthil M, Spilioitis J, Torres-Melero J, Turaga K, Trout R. The American Society of Peritoneal Surface Malignancies (ASPSM) multiinstitution evaluation of the Peritoneal Surface Disease Severity Score (PSDSS) in 1,013 patients with colorectal cancer with peritoneal carcinomatosis. Ann Surg Oncol. 2014;21(13):4195–201.CrossRefPubMedGoogle Scholar
  5. 5.
    McQuellon RP, Russell GB, Shen P, Stewart JH, Saunders W, Levine EA. Survival and health outcomes after cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for disseminated peritoneal cancer of appendiceal origin. Ann Surg Oncol. 2008b;15(1):125–33.CrossRefPubMedGoogle Scholar
  6. 6.
    Zhu Y, Hanna N, Boutros C, Alexander HR Jr. Assessment of clinical benefit and quality of life in patients undergoing cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) for management of peritoneal metastases. J Gastrointest Oncol. 2013;4(1):62–71.PubMedPubMedCentralGoogle Scholar
  7. 7.
    Albertsmeier M, Hauer A, Niess H, Werner J, Graeb C, Angele MK. Quality of life in peritoneal carcinomatosis: a prospective study in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). Dig Surg. 2014;31(4–5):334–40.CrossRefPubMedGoogle Scholar
  8. 8.
    Polom K, Marano L, Roviello G, Petrioli R, Piagnerelli R, de Franco L, Marrelli D, Roviello F. Evolution and emerging future of cytoreducxtive surgery and hyperthermic intraperitoneal chemoperfusion in gastric cancer: from treating the incurable to preventing recurrence. Int J Hyperth. 2015;32:1–7.Google Scholar
  9. 9.
    Sharma A, Walker LG, Monson JR. Baseline quality of life factors predict long term survival after elective resection for colorectal cancer. Int J Surg Oncol. 2013;2013:269510.  https://doi.org/10.1155/2013/269510.PubMedPubMedCentralGoogle Scholar
  10. 10.
    Dodson RM, McQuellon RP, Mogal HD, Duckworth KE, Russell GB, Votanopoulos KI, Shen P, Levine EA. Quality-of-life evaluation after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2016;23(Suppl 5):772–83.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Chia CS, Tan GH, Lim C, Soo KC, Teo MC. Prospective quality of life study for colorectal cancer patients with peritoneal carcinomatosis undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2016;23(9):2905–13.CrossRefPubMedGoogle Scholar
  12. 12.
    Passot G, Bakrin N, Roux AS, Vaudoyer D, Gilly FN, Glehen O, Cotte E. Quality of life after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy: a prospective study of 216 patients. Eur J Surg Oncol. 2014;40(5):529–35.CrossRefPubMedGoogle Scholar
  13. 13.
    Hill AR, McQuellon RP, Russell GB, Shen P, Stewart JH, Levine EA. Survival and quality of life following cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis of colonic origin. Ann Surg Oncol. 2011;18(13):3673–9.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Kirby R, Liauw W, Zhao J, Morris D. Quality of life study following cytoreductive surgery and intraperitoneal chemotherapy for pseudomyxoma peritonei including redo procedures. Int J Surg Oncol. 2013;2013:461041.  https://doi.org/10.1155/2013/461041.PubMedPubMedCentralGoogle Scholar
  15. 15.
    McQuellon R, Gavazzi C, Piso P, Swain D, Levine E. Quality of life and nutritional assessment in peritoneal surface malignancy (PSM): recommendations for care. J Surg Oncol. 2008a;98(4):300–5.CrossRefPubMedGoogle Scholar
  16. 16.
    Hamilton TD, Taylor EL, Cannell AJ, McCart JA, Govindarajan A. Impact of major complications on patients’ quality of life after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2016;23(9):2946–52.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2018

Authors and Affiliations

  • Julianna P. Englisch
    • 1
  • Andreas Brandl
    • 1
  • Ute Goerling
    • 2
  • Beate Rau
    • 1
  1. 1.Department of SurgeryCampus Virchow-Klinikum and Charité Campus Mitte, Charité – Universitätsmedizin BerlinBerlinGermany
  2. 2.Charité Comprehensive Cancer Center, Charité – Universitätsmedizin BerlinBerlinGermany

Personalised recommendations